OBJECTIVES: : This study aimed to compare the effects of different antifungal therapies for invasive candidiasis. METHODS: Literature searches through MEDLINE, and the Cochrane Database were performed with the following search terms: names of  specific antifungal agents, candidiasis and candidemia, from inception to December 2009. We included all randomized controlled trials (RCT), observational studies, cohort studies and review articles that compared different antifungal agents for the treatment of invasive candidiasis and other form of candidiasis. Then we performed a meta-analysis with extracted RCTs. The primary outcome was treatment success and the secondary outcome was all-cause mortality.  Relative risks (RRs) with 95% confidence intervals (Cis) were pooled. RESULTS: Through systematic review (SR), a total number of 9 RCTs, 4 SR and meta-analysis, 1 observational study were extracted. Meta-analysis included 9 RCTs enrolling a total of 1,527 patients. For primary analysis of treatment success, we pooled 5 trials comparing fluconazole to amphotericin B, Relative Risk [RR] 0.92 (95% CI, 0.81-1.03). We also pooled 2 trials of amphotericin B versus echinocandins and yielded a RR of 1.00 (95% CI, 0.90-1.10). One study compared anidulafungin to fluconazole resulting in a RR of 1.26 (95% CI, 1.06-1.51) in favor of anidulafungin. For all-cause mortality analysis, 5 trials assessing fluconazole to amphotericin B were pooled and yielded a RR of 0.84 (95% CI, 0.64-1.12). The pooled RR of 2 trials comparing amphotericin B to echinocandins was 0.95 (95% CI, 0.73-1.23). Anidulafungin versus fluconazole resulted in a RR of 0.73 (95% CI, 0.48-1.10). CONCLUSIONS: All assessed antifungal agents showed similar efficacy on treatment success and all-cause mortality, but anidulafungin revealed the significant high rate of treatment success compared to fluconazole.